References
- Sim DS, Jeong MH, Cho KH, et al. Effect of early statin treatment in patients with cardiogenic shock complicating acute myocardial infarction. Korean Circ J 2013;43:100-9. https://doi.org/10.4070/kcj.2013.43.2.100
- Thiele H, Allam B, Chatellier G, Schuler G, Lafont A. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J 2010;31: 1828-35. https://doi.org/10.1093/eurheartj/ehq220
- Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009;119:1211-9. https://doi.org/10.1161/CIRCULATIONAHA.108.814947
- Champion S, Gauzere BA, Vandroux D. Hypophosphatemia in patients with cardiogenic shock. J Crit Care 2012;27:511. https://doi.org/10.1016/j.jcrc.2012.07.018
- Champion S, Gauzere BA, Lefor Y. Drug-eluting stents should not be used in ST-elevated myocardial infarction with cardiogenic shock. Arch Intern Med 2012;172:1613-4. https://doi.org/10.1001/archinternmed.2012.4418
- Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One 2011;6:e28124. https://doi.org/10.1371/journal.pone.0028124
- Koreny M, Karth GD, Geppert A, et al. Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 2002;112:115-9. https://doi.org/10.1016/S0002-9343(01)01070-1
Cited by
- Dobutamine Infusion and Absence of Pulmonary Hypertension Are Associated with Decreased Mortality in a Cohort of 249 Patients with Cardiogenic Shock vol.6, pp.18, 2014, https://doi.org/10.4236/health.2014.618277